AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS

AtriCure (NASDAQ:ATRC) released its quarterly earnings results on Tuesday. The medical device company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10, FiscalAI reports. The firm had revenue of $140.50 million for the quarter, compared to the consensus estimate of $140.50 million. AtriCure had a negative return on equity of 2.54% and a negative net margin of 5.55%.The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.33) EPS.

Here are the key takeaways from AtriCure’s conference call:

• AtriCure closed 2025 with $534.5M revenue (+15%), $61.8M adjusted EBITDA and $45M cash generated, and reaffirmed 2026 guidance of $600–610M (12%–14% growth) with an adjusted EBITDA target of $80–82M, signaling stronger profitability and cash generation.
• New product traction drove growth — launches like cryoSPHERE MAX, AtriClip FLEX/PRO MINI, EnCompass clamp and CryoXT contributed to outsized gains (pain management +33% worldwide; open appendage +19%) and supported modest gross margin expansion.
• Clinical progress is a strategic catalyst — the randomized LEAPS trial completed enrollment (~6,500+ patients) and the BOX X NoAF 960‑patient trial is underway, which the company says could materially expand the addressable market and shift standards of care (timing of definitive readouts remains uncertain).
• Rapid adoption of PFA is a meaningful headwind to the minimally invasive/hybrid AF franchise, with full‑year MIS revenues down ~26% worldwide and the company expecting continued, albeit moderated, pressure in 2026.
• International reimbursement pressures, especially in the U.K., caused a notable Q4 decline (UK run‑rate fell from ~$4M/quarter to ~ $1M), and management expects UK uncertainty to persist through 2026, weighing on near‑term international growth.

AtriCure Stock Performance

NASDAQ:ATRC opened at $32.97 on Wednesday. The company has a current ratio of 3.87, a quick ratio of 2.85 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.64 billion, a P/E ratio of -54.05 and a beta of 1.41. The firm has a 50-day moving average price of $38.77 and a two-hundred day moving average price of $36.80. AtriCure has a twelve month low of $28.29 and a twelve month high of $43.18.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ATRC shares. Citigroup restated an “outperform” rating on shares of AtriCure in a research report on Wednesday. Canaccord Genuity Group upped their price objective on shares of AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. JPMorgan Chase & Co. cut AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price target for the company. in a report on Wednesday, February 11th. Needham & Company LLC reissued a “buy” rating and set a $45.00 price objective on shares of AtriCure in a report on Thursday, February 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $52.83.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: BTIG reiterated a Buy and maintained a $54 price target, citing sustained outperformance and undervalued growth — this authoritative analyst support can boost investor confidence. AtriCure: Sustained Outperformance, Manageable Competition, and Undervalued Growth Support Buy Rating and $54 Target
• Positive Sentiment: Company beat quarterly EPS and matched revenue expectations while issuing strong guidance; market reports say shares surged on the beat and outlook — the combination of profit beat and constructive forward commentary likely drove the stock higher. AtriCure shares surge as company beats Q4 expectations, issues strong guidance
• Positive Sentiment: Company press release: AtriCure reported full‑year 2025 revenue +15% and said it strengthened profitability while advancing key innovations — the underlying revenue growth and margin progress support a bullish view on execution. AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
• Neutral Sentiment: Yahoo/Seeking Alpha published earnings call highlights and full transcripts — useful for parsing management’s detail on procedure volumes, international trends, and margin drivers but not new headline news. AtriCure Inc (ATRC) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic …
• Neutral Sentiment: Analyst/coverage pieces (Zacks, Benzinga) provide metric breakdowns and forward estimate context — helpful for modeling, but they largely reiterate the beat and guidance. Here’s What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
• Negative Sentiment: Despite the beat, AtriCure remains unprofitable on a GAAP basis (negative net margin ~5.6% and negative ROE) and analysts expect negative FY EPS — ongoing path to sustained profitability and cash generation remains a risk for valuation. AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates

Insider Activity

In other news, insider Justin J. Noznesky sold 5,166 shares of the company’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total value of $192,640.14. Following the sale, the insider directly owned 78,798 shares in the company, valued at $2,938,377.42. This represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Maggie Yuen sold 3,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $35.72, for a total transaction of $107,160.00. Following the sale, the director directly owned 11,371 shares in the company, valued at $406,172.12. This represents a 20.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 18,166 shares of company stock worth $676,378 over the last ninety days. 3.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ATRC. AQR Capital Management LLC boosted its holdings in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after purchasing an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after purchasing an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in AtriCure by 1.0% during the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after buying an additional 8,956 shares during the period. Jane Street Group LLC lifted its position in AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after buying an additional 87,553 shares during the period. Finally, Strs Ohio acquired a new stake in AtriCure in the 1st quarter worth about $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.